Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Pocai

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of Peptide Science : an Official Publication of the European Peptide Society|February 5, 2011
DPP-IV-resistant, long-acting oxyntomodulin derivativesAlessia Santoprete, Elena Capitò, Paul E Carrington, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|November 14, 2013
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptidePhilippe Neuner, Andrea M Peier, Fabio Talamo, et al.
Science (New York, N.Y.)|February 21, 2004
Regulation of fasted blood glucose by resistinRonadip R Banerjee, Shamina M Rangwala, Jennifer S Shapiro, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in miceJoel P Berger, Ranabir SinhaRoy, Alessandro Pocai, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-FluorinationHui Huang, Sanath K Meegalla, James C Lanter, et al.
Diabetes|July 16, 2009
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in miceAlessandro Pocai, Paul E Carrington, Jennifer R Adams, et al.
The New England Journal of Medicine|July 31, 2024
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLDElisa Fabbrini, Brian Rady, Anastasiya Koshkina, et al.
Journal of Medicinal Chemistry|June 14, 2011
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemiaRenata M Oballa, Liette Belair, W Cameron Black, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2024
Pan AMPK Activation Protects Tubules in Rat Ischemic Acute Kidney InjuryHenriette Frikke-Schmidt, Kamal Albarazanji, Jenson Qi, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Pan AMPK activation protects tubules in rat ischemic acute kidney injuryHenriette Frikke-Schmidt, Kamal Albarazanji, Jenson Qi, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of Peptide Science : an Official Publication of the European Peptide Society|February 5, 2011
DPP-IV-resistant, long-acting oxyntomodulin derivativesAlessia Santoprete, Elena Capitò, Paul E Carrington, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|November 14, 2013
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptidePhilippe Neuner, Andrea M Peier, Fabio Talamo, et al.
Science (New York, N.Y.)|February 21, 2004
Regulation of fasted blood glucose by resistinRonadip R Banerjee, Shamina M Rangwala, Jennifer S Shapiro, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in miceJoel P Berger, Ranabir SinhaRoy, Alessandro Pocai, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-FluorinationHui Huang, Sanath K Meegalla, James C Lanter, et al.
Diabetes|July 16, 2009
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in miceAlessandro Pocai, Paul E Carrington, Jennifer R Adams, et al.
The New England Journal of Medicine|July 31, 2024
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLDElisa Fabbrini, Brian Rady, Anastasiya Koshkina, et al.
Journal of Medicinal Chemistry|June 14, 2011
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemiaRenata M Oballa, Liette Belair, W Cameron Black, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 7, 2024
Pan AMPK Activation Protects Tubules in Rat Ischemic Acute Kidney InjuryHenriette Frikke-Schmidt, Kamal Albarazanji, Jenson Qi, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Pan AMPK activation protects tubules in rat ischemic acute kidney injuryHenriette Frikke-Schmidt, Kamal Albarazanji, Jenson Qi, et al.
Pageof 7